A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Trial Profile

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Cetuximab; Docetaxel; Everolimus; Paclitaxel
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 Mar 2016 Planned number of patients changed from 189 to 261, according to ClinicalTrials.gov record.
    • 24 Mar 2016 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top